skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
español
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page


<< Back

Funding

Innovative Assays to Quantify the Latent HIV Reservoir (R01)

Description
Grant Amount: NIAID intends to commit $1.3 million in FY 2015 to fund 2-4 awards.

The goal of this FOA is to support research on the development of innovative high-throughput approaches for quantifying the very low levels of latently infected cells that persist in HIV-positive individuals on HAART. Ideally, a new assay is needed that specifically quantifies resting CD4 memory T cells that contain integrated, replication-competent provirus. The key challenges to be overcome are: (1) the low frequency of these cells (only about 1 in 106 resting cells contains functional provirus), (2) the lack of cell surface markers distinguishing latently infected cells from uninfected cells, and (3) the abundance of defective HIV DNA (only about 1% of HIV DNA in resting CD4 T cells represents replication-competent provirus).

One example of a new approach would be to develop a molecular assay that quantifies integrated, full-length provirus, coupled with sequence analysis to predict replication competence. Such an assay could potentially have higher throughput, faster turnaround, lower cost, and greater reproducibility than the Q-VOA.

Other approaches that quantify latent HIV reservoirs are also of interest if they address the three key challenges listed above and correlate with the level of replication-competent virus present in latently infected cells as determined by Q-VOA.

Improvements to the Q-VOA are also needed and are supported under this FOA. An example of an approach to improve the Q-VOA would be miniaturization of the assay to allow high-throughput analysis of single cells. Another approach might employ highly sensitive indicator cells to eliminate the need for extended co-culture with donor PBMC feeder cells and to provide a more efficient, quantitative endpoint.

Applications that leverage inter-disciplinary collaborations to apply cutting-edge technologies to address these challenges are especially encouraged. It is highly recommended that applications propose to validate the approach by comparison to the existing Q-VOA. While transformed cell lines and primary cell models for latent HIV may be used for initial assay development work, it is imperative that validation studies be extended to include the use of latently infected cells from HIV-positive individuals on optimized HAART. Applications proposing to develop assays for measuring the latent viral reservoir in animal models of HIV/SIV in the context of suppressive HAART regimens will also be considered responsive to the FOA.

Through various sponsored grants and contracts, the NIAID can provide to the research community limited resources in the form of Q-VOA services and access to latently infected resting T cells from HIV-positive individuals. Applicants may inquire about these resources by contacting the Scientific/Research Contact listed in Section VII. Agency Contact(s) of this FOA.
Funding Organization
National Institute of Allergy and Infectious Diseases
Division of AIDS
Fund Category
HIV/AIDS
Support Types
Research
Locations
International
National
Eligible Organizations
City Agencies
Colleges/Universities
Commercial Organizations
Community Based Organizations
County Agencies
Educational Organizations/Institutions
Federal Government Agencies
International Agencies
IRS 501 (c)(3) Organizations
Nonprofit Organizations
Religious Organizations
Schools
State Agencies
Tribal Organizations
Number of Awards Given
2 to 4 awards
Award Amount Notes
NIAID intends to commit $1.3 million in FY 2015 to fund 2-4 awards.
Letter of Intent Date
10/7/2014
Application Due Date
11/7/2014
Project Start Date
7/1/2015
Application Contact
GrantsInfo
,
Phone: (301) 435-0714
Technical Contact
Karl Salzwedel
NIAID
Phone: (301) 496-5332
Fund Duration
Up to 5 years.
Subjects
Antiretroviral Drugs
HIV Positive Persons
Research Programs
Audiences
Researchers
Application Process
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Web Site
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-020.html
Fund Number
RFA-AI-14-020

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.

cdcnpin.org Fund Record #4856

<< Back

CDCNPIN.org

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources

hivtest.cdc.gov
m.hivtest.cdc.gov
findtbresources.org
STD Awareness Microsite
findstdtest.org
AIDS Gov Logo and Link CDC Logo and Link